Search research articles
Contact Us
Filters
Showing results (341-350 of 346) with videos related to
Page
of 35
Sort By:
You have reached the last page of results.
This site can display upto 346 results.
Leukemia
|
February 25, 2025
Long term results of venetoclax combined with FLAG-IDA induction and consolidation for newly diagnosed and relapsed or refractory acute myeloid leukemia
Courtney D DiNardo, Wei-Ying Jen, Koichi Takahashi, et al.
Leukemia
|
December 10, 2025
Correction: Long term results of venetoclax combined with FLAG-IDA induction and consolidation for newly diagnosed and relapsed or refractory acute myeloid leukemia
Courtney D DiNardo, Wei-Ying Jen, Koichi Takahashi, et al.
The Lancet. Haematology
|
September 8, 2020
10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial
Courtney D DiNardo, Abhishek Maiti, Caitlin R Rausch, et al.
Blood Cancer Discovery
|
January 26, 2026
Incorporation of genomic determinants improves diagnostic accuracy of oligomonocytic chronic myelomonocytic leukemia
Guillermo Montalban-Bravo, Chong Wu, Juan Jose Rodriguez-Sevilla, et al.
Nature Cancer
|
September 19, 2024
Glutaminase inhibition in combination with azacytidine in myelodysplastic syndromes: a phase 1b/2 clinical trial and correlative analyses
Courtney D DiNardo, Divij Verma, Natalia Baran, et al.
Leukemia
|
August 23, 2024
Menin inhibitors in pediatric acute leukemia: a comprehensive review and recommendations to accelerate progress in collaboration with adult leukemia and the international community
Branko Cuglievan, Hagop Kantarjian, Jeffrey E Rubnitz, et al.
Page
of 35
Search research articles
Search
Showing results (341-350 of 346) with videos related to
Sort By:
Page
of 35
You have reached the last page of results.
This site can display upto 346 results.
Leukemia
|
February 25, 2025
Long term results of venetoclax combined with FLAG-IDA induction and consolidation for newly diagnosed and relapsed or refractory acute myeloid leukemia
Courtney D DiNardo, Wei-Ying Jen, Koichi Takahashi, et al.
Leukemia
|
December 10, 2025
Correction: Long term results of venetoclax combined with FLAG-IDA induction and consolidation for newly diagnosed and relapsed or refractory acute myeloid leukemia
Courtney D DiNardo, Wei-Ying Jen, Koichi Takahashi, et al.
The Lancet. Haematology
|
September 8, 2020
10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial
Courtney D DiNardo, Abhishek Maiti, Caitlin R Rausch, et al.
Blood Cancer Discovery
|
January 26, 2026
Incorporation of genomic determinants improves diagnostic accuracy of oligomonocytic chronic myelomonocytic leukemia
Guillermo Montalban-Bravo, Chong Wu, Juan Jose Rodriguez-Sevilla, et al.
Nature Cancer
|
September 19, 2024
Glutaminase inhibition in combination with azacytidine in myelodysplastic syndromes: a phase 1b/2 clinical trial and correlative analyses
Courtney D DiNardo, Divij Verma, Natalia Baran, et al.
Leukemia
|
August 23, 2024
Menin inhibitors in pediatric acute leukemia: a comprehensive review and recommendations to accelerate progress in collaboration with adult leukemia and the international community
Branko Cuglievan, Hagop Kantarjian, Jeffrey E Rubnitz, et al.
Page
of 35